These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 20207825

  • 1. Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.
    Birzniece V, Meinhardt U, Gibney J, Johannsson G, Baxter RC, Seibel MJ, Ho KK.
    J Clin Endocrinol Metab; 2010 May; 95(5):2099-106. PubMed ID: 20207825
    [Abstract] [Full Text] [Related]

  • 2. Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.
    Birzniece V, Meinhardt UJ, Gibney J, Johannsson G, Armstrong N, Baxter RC, Ho KK.
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1005-12. PubMed ID: 22170716
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women.
    Gibney J, Johannsson G, Leung KC, Ho KK.
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3897-903. PubMed ID: 15855258
    [Abstract] [Full Text] [Related]

  • 4. Effects of raloxifene and estrogen on bioactive IGF1 in GH-deficient women.
    Birzniece V, Magnusson NE, Ho KK, Frystyk J.
    Eur J Endocrinol; 2014 Mar; 170(3):375-83. PubMed ID: 24347426
    [Abstract] [Full Text] [Related]

  • 5. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.
    Birzniece V, Sutanto S, Ho KK.
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E521-7. PubMed ID: 22319035
    [Abstract] [Full Text] [Related]

  • 6. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM, Duong T, Pliester N, Asma G, Popp-Snijders C, Lips P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ, Fisker S, Gravholt CH, Bennett P, Svenstrup B, Andersen M, Feldt-Rasmussen U, Christiansen JS, Jørgensen JO.
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Estrogens exert route- and dose-dependent effects on insulin-like growth factor (IGF)-binding protein-3 and the acid-labile subunit of the IGF ternary complex.
    Kam GY, Leung KC, Baxter RC, Ho KK.
    J Clin Endocrinol Metab; 2000 May; 85(5):1918-22. PubMed ID: 10843175
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women.
    Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK.
    Am J Physiol Endocrinol Metab; 2001 Dec; 281(6):E1191-6. PubMed ID: 11701433
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Interaction between testosterone and growth hormone on whole-body protein anabolism occurs in the liver.
    Birzniece V, Meinhardt UJ, Umpleby MA, Handelsman DJ, Ho KK.
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1060-7. PubMed ID: 21239519
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women.
    O'Sullivan AJ, Crampton LJ, Freund J, Ho KK.
    J Clin Invest; 1998 Sep 01; 102(5):1035-40. PubMed ID: 9727072
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose in patients with hypopituitarism during GH treatment: a randomized study.
    Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA.
    Eur J Endocrinol; 2012 Feb 01; 166(2):207-13. PubMed ID: 22108915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.